Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.

BD alleges Cytek hired away former BD employees to develop flow cytometry products to compete against BD.

An analysis of several multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing risk of late distant recurrence.

They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.

Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.